Back to Search Start Over

The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions.

Authors :
Pak AC
Ashby CR Jr
Heidbreder CA
Pilla M
Gilbert J
Xi ZX
Gardner EL
Source :
The international journal of neuropsychopharmacology [Int J Neuropsychopharmacol] 2006 Oct; Vol. 9 (5), pp. 585-602. Date of Electronic Publication: 2006 Aug 31.
Publication Year :
2006

Abstract

Increasing evidence suggests that enhanced dopamine (DA) neurotransmission in the nucleus accumbens (NAc) may play a role in mediating the reward and reinforcement produced by addictive drugs and in the attentional processing of drug-associated environmental cues. The meso-accumbens DA system is selectively enriched with DA D3 receptors, a DA receptor subtype increasingly implicated in reward-related brain and behavioural processes. From a variety of evidence, it has been suggested that selective DA D3 receptor antagonism may be a useful pharmacotherapeutic approach for treating addiction. The present experiments tested the efficacy of SB-277011A, a selective DA D3 receptor antagonist, in rat models of nicotine-enhanced electrical brain-stimulation reward (BSR), nicotine-induced conditioned locomotor activity (LMA), and nicotine-induced conditioned place preference (CPP). Nicotine was given subcutaneously within the dose range of 0.25-0.6 mg/kg (nicotine-free base). SB-277011A, given intraperitoneally within the dose range of 1-12 mg/kg, dose-dependently reduced nicotine-enhanced BSR, nicotine-induced conditioned LMA, and nicotine-induced CPP. The results suggest that selective D3 receptor antagonism constitutes a new and promising pharmacotherapeutic approach to the treatment of nicotine dependence.

Details

Language :
English
ISSN :
1461-1457
Volume :
9
Issue :
5
Database :
MEDLINE
Journal :
The international journal of neuropsychopharmacology
Publication Type :
Academic Journal
Accession number :
16942635
Full Text :
https://doi.org/10.1017/S1461145706006560